Opaleye Management buys $8,001 of Grace Therapeutics common stock

Opaleye Management Inc., a 10% owner and director of Grace Therapeutics, Inc. [GRCE], acquired 4,256 shares of the company’s common stock on October 19, 2026. The transaction totaled $8,001, with shares purchased at a price of $1.88 each.

Following this acquisition, Opaleye Management Inc. indirectly beneficially owns 2,948,610 shares of Grace Therapeutics common stock. The purchase comes as the stock trades near its 52-week low of $1.79, having declined 57.73% over the past six months. According to InvestingPro analysis, GRCE appears undervalued at current levels, with analysts setting price targets ranging from $3.95 to $7.93. The platform reveals that analysts predict the company will be profitable this year, with EPS expected to reach $3.38 in fiscal 2027—one of 7 additional InvestingPro Tips available to subscribers. These securities are directly owned by Opaleye, L.P., and Opaleye Management Inc., as the investment manager of the fund, may be deemed to beneficially own them. However, Opaleye Management Inc. disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest.